An infant scheduled for intramuscular nirsevimab has a platelet count of 18,000/mcL and new petechiae. Which action should the nurse take?

1 Administer the injection without review because monoclonal antibodies cannot cause injection-site bleeding.
2 Hold administration and obtain prompt review of the bleeding risk and the authorized plan. ✓ Correct answer
3 Massage the injection site forcefully for 10 minutes before giving the medication.
4 Change the intramuscular product to an intravenous bolus without a prescription.

Explanation

Nirsevimab is an intramuscular injection that requires caution in clients with thrombocytopenia or another clinically significant bleeding disorder.

Next question on this topicA nurse is reviewing the morning lab results for an adult client receiving warfarin for at…

In-depth explanation

Quick answer
Screen intramuscular biologic administration against severe thrombocytopenia.

Why this is correct
The platelet count and petechiae require an individualized administration decision. Route changes and forceful manipulation are not independent nursing substitutions.

Easy analogy or mental picture
Use a closed medication-safety loop: identify the immune or cytotoxic exposure, connect the new findings, interrupt further harm, stabilize the client, and verify the response over time.

Memory hook
Exposure, immune effect, organ toxicity, infection risk, immediate action, and serial reassessment.

NCLEX decision rule
Choose the action that reduces the most immediate medication-related risk while preserving diagnostic evaluation and authorized treatment.

Why the other choices are wrong
Options that continue the exposure, treat only one symptom, or delay reassessment leave the toxic or infectious process active.

References

1DailyMed: BEYFORTUS (nirsevimab)RSV lower respiratory tract disease prevention, serious hypersensitivity, and caution with bleeding disorders

Clinical scenario

Oncology, transplant, and biologic safety review
Verify the indication, immune status, infection screen, interacting medicines, current organ findings, authorized action, and measurable follow-up.

Browse all questions No login required

Master the NCLEX-RN with MyMerci

Thousands of NCLEX-style questions with detailed rationale — in your language. Track your progress and study smarter.

Start for free

App Store Google Play

Read in another language: English 한국어 日本語繁體中文 Tiếng Việt

For study reference only. Always follow current clinical guidelines and your institution’s protocols.

성장을 멈추지 마세요

An infant scheduled for intramuscular nirsevimab has a platelet count of 18,000/mcL and new petechiae. Which action should the nurse take?

In-depth explanation

Clinical scenario

Master the NCLEX-RN with MyMerci